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Aims/hypothesis: Few studies examine the association between age at diagnosis and 
subsequent complications from type 2 diabetes. This paper aims summarise the risk of 
mortality, macrovascular and microvascular complications associated with age at diagnosis 
of type 2 diabetes. 
Methods: Data were sourced from Medline and All EBM (Evidence Based Medicine) 
databases from inception to July 2018. Observational studies, investigating the effect of age 
at diabetes diagnosis on macrovascular and microvascular diabetes complications in adults 
with type 2 diabetes were selected according to pre-specified criteria. Two investigators 
independently extracted data and evaluated all studies. If data were not reported in a 
comparable format, data were obtained from authors, presented as minimally adjusted odds 
ratios (and 95% confidence intervals) per one year increase in age at diabetes diagnosis, 
adjusted for current age for each outcome of interest. The study protocol was recorded with 
PROSPERO International prospective register of systematic reviews (CRD42016043593).  
Results: Data from 26 observational studies comprising 844 081 individuals from 30 
countries were included. Random effects meta-analyses with inverse variance weighting 
were used to obtain the pooled odds ratios. Age at diabetes diagnosis was inversely 
associated with risk of all-cause mortality, macrovascular and microvascular disease (all 
p<0.001). Each one-year increase in age at diabetes diagnosis was associated with a 4, 3 
and 5% decreased risk of all-cause mortality, macrovascular disease and microvascular 
disease respectively, adjusted for current age. The effects were consistent for the individual 
components of the composite outcomes (all p<0.001). 
Conclusions/interpretation: Younger rather than older, age at diabetes diagnosis was 
associated with higher risk of mortality and vascular disease. Early and sustained 
interventions to delay type 2 diabetes onset and improve glycaemia and cardiovascular risk 
profiles of those already diagnosed are essential to reduce morbidity and mortality. 




RESEARCH IN CONTEXT  
What is already known about this subject? (maximum of 3 bullet points) 
 Type 2 diabetes, conventionally considered a disease of middle and older age, is 
increasingly diagnosed at a younger age.  
 Despite this, the pathogenesis of the long-term vascular complications associated 
with early or late onset type 2 diabetes is not well characterised.  
 Although there are several studies examining the relationship between age at 
diabetes diagnosis and long-term complications among people with type 2 diabetes. 
These studies have varied widely in population characteristics or methodological 
rigour, and report inconsistent findings with some suggesting that younger age at 
diabetes diagnosis is associated with increased risk of complications, decreased risk 
of complications, no difference in risk of complications or variable effects in different 
end organs. 
What is the key question? (one bullet point only; formatted as a question) 
 What is the risk of mortality, macrovascular and microvascular complications 
associated with age at diagnosis of type 2 diabetes mellitus. 
What are the new findings? (maximum of 3 bullet points) 
 This analysis integrates data from over half a million people with diabetes worldwide 
to evaluate the risk of a range of diabetes complications with respect to age at 
diagnosis. 
 Each one-year increase in age at diabetes diagnosis was associated with a 4, 3 and 
5 % decreased risk of all-cause mortality, macrovascular disease and microvascular 
disease, respectively.  
 Further research is needed on how to optimise the cardiovascular risk profiles and 
trajectories of younger as well as older patients with diabetes 
How might this impact on clinical practice in the foreseeable future? (one 
bullet point only) 
 Identification and quantification of the higher risk of mortality and vascular disease 
conferred by younger age at type 2 diabetes diagnosis may enable risk stratification 
of people early in the condition and provide greater opportunities for interventions to 





The International Diabetes Federation estimates that the prevalence of diabetes will rise 
from 425 million people worldwide in 2017, to 629 million by 2045 [1]. Type 2 diabetes, 
conventionally considered a disease of middle and older age, is increasingly diagnosed at a 
younger age [1, 2]. Type 2 diabetes and its associated complications contribute to 8.4% of 
deaths worldwide, consuming significant healthcare resources [3]; this is likely to rise 
exponentially given the increasing prevalence of the condition [1].   
 
Despite significant diagnostic, monitoring and treatment advances, type 2 diabetes remains 
associated with increased mortality and morbidity compared with the general population [4]. 
However, the pathogenesis of the long-term vascular complications associated with early or 
late onset type 2 diabetes is not well characterised, and although the mechanisms for the 
development of complications maybe similar [5], recent evidence suggests an accelerated 
course in people diagnosed with early onset type 2 diabetes [6, 7]. Proposed mechanisms 
include a longer lifetime exposure to the adverse diabetic milieu and/or early onset type 2 
diabetes representing an inherently more aggressive metabolic phenotype with rapid onset 
of β-cell failure and insulin resistance compared to late onset disease [2, 8, 9]. Novel cluster 
analyses raise the possibility of type 2 diabetes representing a clustering of up to five 
disease subgroups with distinct age at diagnosis, genetics, mechanisms of disease 
progression and risk of diabetic complications [10]. Of the five groups identified, the ‘mild 
age-related diabetes’ subgroup contained elderly people who experienced the most benign 
disease course compared with the ‘mild obesity-related diabetes’ group, characterised by 
younger age at onset and obesity.  
 
There are several studies examining the relationship between age at diabetes diagnosis and 
long-term complications among people with type 2 diabetes. These studies have varied 
widely in population characteristics or methodological rigour, and report inconsistent findings 
with some suggesting that younger age at diabetes diagnosis is associated with increased 
risk of complications [6, 7, 11-15], decreased risk of complications [16, 17], no difference in 
risk of complications [18] or variable effects in different end organs [19, 20]. Additionally, 
some studies have proposed that longer diabetes duration [21, 22] or more adverse 
cardiovascular risk profiles [23, 24] underlie the greater risk of development of vascular 
complications associated with type 2 diabetes diagnosed at a younger age, whilst other 




Evidence of a clinically meaningful effect of age at diagnosis of type 2 diabetes beyond the 
ageing process itself would have substantial implications for diabetes prevention, treatment 
and the development and implementation of cardiovascular risk prediction tools. The aim of 
our study was thus to examine the effect of age at diagnosis of type 2 diabetes on risks of 




Data Sources and Searches 
A systematic search of published literature was conducted in Medline and All EBM 
(Evidence Based Medicine) databases (including Cochrane Database of Systematic 
Reviews, ACP Journal Club Database of Abstracts of Reviews of Effects, Cochrane Central 
Register of Controlled Trials, Cochrane Methodology Register, Health Technology 
Assessment and NHS Economic Evaluation Database) using the subject headings and key 
terms detailed in Appendix 1. The study methods and reporting follow the Meta-analyses Of 
Observational Studies in Epidemiology (MOOSE) and Preferred Reporting Items for 
Systematic review and Meta-Analysis (PRISMA) guidelines [26, 27]. The study protocol was 
recorded with PROSPERO International prospective register of systematic reviews 
(CRD42016043593). The search was limited to humans and English language articles and 
was initially conducted in July 2016 with no time restrictions and updated in July 2018.  
 
Study selection 
The inclusion criteria were determined a priori (Appendix 1). To be included, studies had to 
meet the following criteria: be a study of adult participants with type 2 diabetes, investigating 
the effect of age at diabetes diagnosis on macrovascular and microvascular diabetes 
complications. The study had to assess one or more of the following outcome variables (all-
cause mortality, macrovascular disease, microvascular disease, retinopathy, nephropathy, 
neuropathy, cardiovascular disease, cerebrovascular disease and peripheral vascular 
disease) and have an available mortality/complication rate, where mortality was either a pre-
specified primary or secondary outcome, or the methods indicated complete follow-up of 
participants.   
 
Two independent authors (NN and AG) assessed the title and abstracts of retrieved records 
for relevance and duplication. Authors then reviewed the full text of potentially eligible 
 
 
citations to identify studies that fulfilled the inclusion criteria. Any uncertainties regarding 
study inclusion and data extraction were discussed with an experienced systematic reviewer 
(AC), statistician (SH) and senior clinician (SZ). The references cited in the retrieved 
publications were screened for potentially eligible studies. When several articles from the 
same study had reported on the same endpoint, only the data representing the longest 
follow-up were extracted.  
 
Data extraction and quality assessment  
Data were extracted from included studies using a specially developed data extraction form. 
Information was obtained regarding study design and location, participant characteristics, 
outcome variables and results. Given the wide variation in data reporting and adjustment for 
confounders, meaningful interpretation, comparison and meta-analysis was not possible. 
Therefore, we contacted authors to reanalyse and present data in a homogeneous format to 
enable data pooling and comparison. Corresponding authors were contacted by email at 
least twice (if data were not reported in a suitable format) to request data, presented as 
minimally adjusted odds ratios [odds ratio (OR) 95% confidence interval (CI)] per one year 
increase in age at diabetes diagnosis, with adjustment for current age (or diabetes duration) 
for each outcome of interest. This format was chosen as the majority of studies presented 
the results in this way.  
 
Risk of bias of included studies was assessed using a specially developed data extraction 
form, based on the Newcastle–Ottawa Scaling for non-randomized studies [28, 29]. Quality 
assessment criteria included representativeness of participants, validity of the diagnostic 
criteria, determination of age at diagnosis, outcome assessment, withdrawals and losses to 
follow-up. Each study was then allocated a risk of bias rating (Appendix 3). 
 
Exposures 
Current age was reported by each study as age at entry into the study or age at baseline 
assessment. Age at type 2 diabetes diagnosis was reported as the age of the people at the 
diagnosis of type 2 diabetes with diabetes duration reported or calculated as current age 





The primary a priori outcomes were all-cause mortality, macrovascular disease (composite 
of coronary heart disease, cerebrovascular disease and peripheral vascular disease) or 
microvascular disease (composite of retinopathy, nephropathy and neuropathy). The 
secondary a priori outcomes were retinopathy, nephropathy, neuropathy, coronary heart 
disease, cerebrovascular disease and peripheral vascular disease.  
 
Statistical analysis 
Interdependence of current age, age at diabetes diagnosis and diabetes duration precluded 
use of all 3 variables in the same model; hence the use of models containing either age at 
diabetes diagnosis adjusted for current age or age at diabetes diagnosis adjusted for 
diabetes duration. Adjustment for current age was to remove the effect of aging per se. 
Adjustment for diabetes duration was to remove the effect of the time-point at which 
observations happened to be made in the course of illness for each individual; an individual 
observed early in their illness would appear to have a longer time to develop complications 
than the same individual observed late in their illness. For studies reporting in multiple 
models, we extracted data for both minimally adjusted and maximally adjusted increased risk 
estimates.  Unless otherwise stated, the least adjusted risk estimates from each study were 
used, provided diabetes duration was included. Review Manager (RevMan) software Version 
5.3 was used for all statistical analyses [30].  
 
Data were combined in meta-analyses to calculate pooled risk estimates presented as odds 
ratios (OR) and 95% Confidence Interval (CI) of the effect of age at diabetes diagnosis (per 
year) adjusted for current age (or diabetes duration – supplemental analyses), on outcomes 
using both fixed and random-effects models (generic inverse variance method) [31]. There 
were no significant differences between fixed- and random-effects analyses. Random effects 
models are presented given heterogeneity among the studies [32]. Crude data were included 
where possible, given variable control for confounding factors. However, some articles 
presented adjusted ORs only.  
I2 was used to assess heterogeneity with values of 25%, 50%, and 75% considered low, 
moderate and high, respectively [33]. Funnel plots were used to explore potential publication 
bias [34, 35]. A scatter plot of the t-statistic associated with each study estimate value 
assessed the contribution of each study to the study-estimate random effect versus the log 




Characteristics of included studies  
Electronic database and reference searching yielded 2219 publications, of which 156 were 
reviewed in full-text (Figure 1).  Of 34 eligible studies, 26 studies comprising 844 081 
individuals were included and 8 were excluded because data were not provided in the 
required format in the publication and attempts to contact authors were not successful. The 
25 included studies were either cross-sectional (13 studies) or cohort (13 studies) in design. 
The updated search in 2018 enabled the inclusion of data from 3 studies. The mean age of 
study participants ranged from 21.6 to 67.4 years. The proportion of female study 
participants ranged from 42.5% to 68.6%. Table 1 summarises the characteristics of the 
included studies which comprise 844 081 participants from 30 countries worldwide.  
 
PRIMARY OUTCOMES  
Effects of age at diabetes diagnosis adjusted for current age on all-cause mortality, 
macrovascular disease and microvascular disease 
For all-cause mortality, data from 5 studies [20, 21, 25, 36, 37], comprising 844 081 
participants indicated that each one year increase in age at diabetes diagnosis was 
associated with a 4% decreased risk of all-cause mortality (OR 0.96 [0.94, 0.98], p<0.001) 
when adjusted for current age. For macrovascular disease, data from 8 studies [20, 23-25, 
37-40], comprising 356 008 participants indicated that each one year increase in age at 
diabetes diagnosis was associated with a 3% decreased risk of macrovascular disease (OR 
0.97 [0.96, 0.98], p<0.001) when adjusted for current age. For microvascular disease, data 
from 8 studies [20, 24, 25, 38-42] comprising 147 502 participants indicated that each one 
year increase in age at diabetes diagnosis was associated with a 5% decreased risk of 
microvascular disease (OR 0.95 [0.94, 0.96], p<0.001) when adjusted for current age. 
Significant heterogeneity in the magnitude of the effects was evident between studies for 
these outcomes (all Chi2 p=<0.001, all I2  93 %) (Figure 2).  
SECONDARY OUTCOMES  
Effects of age at diabetes diagnosis adjusted for current age on coronary heart 
disease, cerebrovascular disease, peripheral vascular disease, retinopathy, 
nephropathy and neuropathy) 
Data for individual vascular complications were available from 13 studies, comprising 356 
038 participants and adjusted for current age.  Each one year increase in age at diabetes 
diagnosis was associated with a 2% decreased risk of coronary heart disease (OR 0.98 
 
 
[0.97, 0.98], p<0.001), a 2% decreased risk of cerebrovascular disease (OR 0.98 [0.97, 
0.99], p<0.001) and a 3% decreased risk of peripheral vascular disease (OR 0.97 [0.96, 
0.99], p<0.001). Each one year increase in age at diabetes diagnosis was associated with 
an 8% decreased risk of retinopathy (OR 0.92 [0.90, 0.95], p<0.001), a 6% decreased risk of 
nephropathy (OR 0.94 [0.92, 0.96], p<0.001) and a 5% decreased risk of neuropathy (OR 
0.95 [0.94, 0.96], p<0.001) (Figure 3). Significant heterogeneity in the magnitude of the 
effects was evident between studies for these outcomes (all Chi2 p= <0.001, all I2  48%).  
 
SENSITIVITY ANALYSES 
Effects of age at diabetes diagnosis adjusted for diabetes duration on all-cause 
mortality, macrovascular disease and microvascular disease 
Data for these analyses were obtained from ten studies comprising 390 139 participants and 
adjusted for diabetes duration (ESM figure 1). Each one year increase in age at diabetes 
diagnosis was associated with a 6% increased risk of all-cause mortality (OR 1.06 [1.03, 
1.09], p<0.001), a 6% increased risk of macrovascular disease (OR 1.06 [1.04, 1.07], 
p<0.001) and a 5% increased risk of microvascular disease (OR 1.05 [1.02, 1.08], p<0.001). 
 
Methodological quality 
Risk of bias assessment of the included studies is presented in Appendix 3. Study 
participants were recruited to randomised clinical trials or selected from large clinical 
datasets. Inclusion and exclusion criteria were adequately described in all studies. Of the 
included studies 24 [14, 15, 20, 21, 23-25, 36-52] were of high quality and 2 [53, 54] of 
medium quality due to insufficient adjustment of confounding variables. In addition, 24 
studies [14, 15, 20, 21, 23-25, 36-52] demonstrated low risk of bias and 2 [53, 54] 
demonstrated a moderate risk of bias due to insufficient adjustment for confounding 
variables (confounding bias) (ESM table 3). Funnel plots did not suggest the presence of 
publication bias (ESM figure 2). 
 
CONCLUSIONS 
This comprehensive systematic review and meta-analysis compiles the results of 25 studies 
investigating the effects of age at diabetes diagnosis on mortality and subsequent 
complications in 844 081 participants with type 2 diabetes from diverse populations across 
the Asia Pacific, Europe and North America. We report an inverse relationship between age 
at diabetes diagnosis and risk of major diabetes complications after adjustment for current 
 
 
age. Each one-year increase in age at diabetes diagnosis was associated with a 4, 3 and 
5% decreased risk of all-cause mortality, macrovascular disease and microvascular disease 
respectively.  These effects were consistent across the individual components of the 
composite outcomes (coronary heart disease, cerebrovascular disease, peripheral vascular 
disease, retinopathy, nephropathy and neuropathy) and reversed when the models included 
diabetes duration rather than current age. 
 
While prior studies have assessed the effects of age at diabetes diagnosis on diabetes 
complications, to our knowledge, this is the first systematic review and meta-analysis 
exploring associations between age at diabetes diagnosis and subsequent outcomes. 
Interdependence of current age, age at diabetes diagnosis and diabetes duration precluded 
investigation of all 3 variables simultaneously; hence the use of models containing either age 
at diabetes diagnosis adjusted for current age or age at diabetes diagnosis adjusted for 
diabetes duration. Those diagnosed with diabetes at older age may be more likely to have 
accumulated adverse cardiovascular risk factors compared with those diagnosed at a 
younger age. Since advancing age is a powerful predictor of vascular complications, for the 
same diabetes duration, people with younger age at diagnosis are likely to have lower 
absolute risks of events as compared to people with older age at diagnosis. Over time 
however, the effects of both aging and disease duration may be amplified resulting in 
premature complications and death in people diagnosed with type 2 diabetes at a younger 
age. For example a person diagnosed with type 2 diabetes at age 30 years would have a 
lower absolute risk of complications compared with another person diagnosed age 50 years, 
however by the time they both reach 60 years, the person diagnosed at a younger age 
would have a higher relative and absolute risk due to the effects of ageing, compounded by 
the effects of longer diabetes duration. This pattern has been observed in several young 
onset type 2 diabetes populations [21, 55]. Thus, younger people pose a significant 
challenge for clinicians and decision makers who need to be aware of these compounding 
pathologies of natural ageing and premature vascular aging associated with type 2 diabetes. 
Further, people diagnosed at a younger age still have the potential to develop type 2 
diabetes complications at an earlier stage of life age, at a time when they are more likely to 
cause greater disability and loss of productivity compared with people diagnosed at an older 
age. 
 
There are lack of RCT studies on achieving good glycaemic control and optimisation of 
cardiovascular risk factors in young-onset type 2 diabetes, as many of these trials recruited 
 
 
middle-aged people with long disease duration at greatest absolute risk of complications. 
However, data from these older populations may not reflect the pathophysiology of type 2 
diabetes in younger people, given evidence suggesting that younger and older patients may 
differ in the development of diabetes complications. Further, many of these studies lack 
sufficient follow up to capture complications in younger people who may have a longer time 
to event. The observations of this study and others examining type 2 diabetes complications 
[15, 23, 38, 51] add impetus to conducting trials examining this young cohort. There is an 
urgent need for data specifically pertaining to younger type 2 diabetes populations 
examining the trajectory of vascular complications and the impact of interventions 
(pharmacological as well as non-pharmacological approaches) to improve outcomes.  
 
We found that age at diabetes diagnosis adjusted for current age was inversely associated 
with risk of all-cause death, macrovascular and microvascular disease. Our findings 
underscore the importance of cardiovascular risk management among people with diabetes. 
Screening for and prevention of macrovascular complications is particularly important for 
older people with diabetes who have the highest short-term absolute risk. Increasing age 
remains one of the most important risk factors for the development of macrovascular 
complications. However, it is also important to note that people diagnosed with diabetes at a 
younger age have longer lifetime risk of developing significant complications, thus achieving 
good glycaemic control and optimisation of cardiovascular risk factors is of particular 
importance across their lifespan. This difference in risk between younger and older people in 
terms of absolute vs lifetime risks of type 2 diabetes complications, should perhaps be 
recognised in diabetes management guidelines with increased promotion of screening 
programs in older people with type 2 diabetes and a greater emphasis on preventive 
measures for younger patients with type 2 diabetes.  
 
As early intensive multifactorial risk factor intervention is important for the prevention of long 
term macrovascular complications among people with newly diagnosed diabetes [56], our 
findings further suggest that this should be sustained long-term to minimise risks over time. 
Clearly, strategies are needed to ensure sustained adherence to lifestyle behaviours and 
therapies proven to have cardiovascular benefits among people with diabetes. Existing 
treatment guidelines are limited by being reactive to suboptimal glycaemic control after it has 
developed, but do not have means to predict which people require intensified treatment. 
Refined stratification using age at diagnosis, may provide a method of identifying at 
diagnosis those at greatest risk of complications who would most benefit from targeted, 
 
 
individualised treatment regimens. Moreover, public health measures to delay and/or prevent 
the onset of type 2 diabetes to older age may yield benefits by reducing the duration of 
diabetes and burden of complications.   
 
The development and progression of type 2 diabetes represents a complex interplay 
between genetic, epi-genetic, lifestyle, demographic, socio-economic, therapeutic and 
environmental factors. Given the myriad factors involved, and the variable reporting across 
included studies, it was difficult to establish uniformity in study definitions and co-variate 
adjustment across studies. There was considerable variation in the definitions of “younger” 
and “older” age at type 2 diabetes diagnosis, with some studies defining “younger” as less 
than 30 years of age, less than 40 years or less than 50 years of age. To mitigate this, we 
examined the effect of age at diabetes diagnosis (adjusted for current age), in yearly 
increments. Studies varied greatly with respect to measured confounding factors such as 
ethnicity, study country and year, type 2 diabetes diagnostic criteria, medication use, 
glycaemic control age, obesity, cardio-metabolic risk factors, co-morbid conditions, 
recruitment, source of participants, family history, healthcare access and sociodemographic 
factors. We were unable to adjust for these factors, as this data was either unavailable or not 
comparable due to the lack of standardised definitions across published studies. Moving 
forward, standardised approaches to reporting and complete data capture of relevant 
variables will assist with pooling and analysis of disparate datasets. This may be facilitated 
by the creation of international data registries. Performance bias (a potential difference in the 
care provided between early and later onset type 2 diabetes groups and between different 
centres) could not be assessed. Older people with type 2 diabetes may have cognitive 
impairment or other comorbidities precluding treatment intensification or even leading to de-
intensification. Alternatively, people diagnosed with type 2 diabetes at a younger age may 
have been treated more intensively than people diagnosed at an older age. If this were the 
case, this bias would ameliorate the differences between groups, such that our data may 
actually underestimate the true extent of the effect of younger age at type 2 diabetes 
diagnosis. However, this would seem less likely as several studies suggest that younger 
people with type 2 diabetes have poorer glycaemic control, lower adherence to therapy and 
inferior self-care practices compared with older people [57, 58]. In fact, the data suggests 
that younger people with type 2 diabetes may receive suboptimal medical attention was 
given to younger patients, potentially due in part, to an absence of clinical guidelines 
targeted to younger people with type 2 diabetes and possibly the underestimation of risks of 




The strength of this meta-analysis is the extensive and comprehensive literature search and 
focus on studies examining younger and older people with type 2 diabetes. Six databases 
were searched, a risk of bias appraisal performed, and reanalyses were undertaken, 
enabling inclusion of data from more than half a million people with type 2 diabetes 
worldwide. Collaboration with other authors facilitated more homogeneous data definitions, 
data integration, and meta-analyses. We found that there was high concordance between 
the different studies in the meta-analyses, such that the direction of the effects were 
consistent, although the magnitude of effects and the confidence intervals varied. This may 
be due to differences in study size, however contributions from genetic, ethnic and 
healthcare variations in study populations cannot be excluded. Nevertheless, the direction of 
the effects was consistent across the studies from different countries. 
 
As with many systematic reviews and meta-analyses, this meta-analysis has some 
limitations. Not all identified studies were included in the meta-analyses due to difficulties 
sourcing comparable data from authors. The inability to acquire data from all eligible studies 
is not unexpected and is a part of the meta-analysis process [59]. We based our 
classification of age at type 2 diabetes diagnosis on the definitions used in each individual 
study, even though these definitions may have differed. It would be impossible to apply 
retrospectively a single definition of age at diagnosis to a large number of samples 
characterised with different variables in different studies. Additionally, the criteria for the 
diagnosis and classification of type 2 diabetes have changed with the advent of new 
technologies such as the determination of pancreatic auto-antibodies and C-peptide levels, 
as have the methods used to differentiate type 2 from other forms of diabetes (principally 
type 1 and monogenic diabetes). Lastly, due in part to the nature of the study question, the 
included studies were observational in design and therefore subject to potential the biases 
(confounding and selection) inherent to analyses of observational data. However, meta-
analyses of observational studies can provide valuable insights, especially when randomised 
clinical trials are unavailable or inappropriate to address the question [34] as is the case 
here. Findings from this review are based on observational data and therefore causality may 
not be attributed. Thus, although these findings may be applicable on a population level, any 
recommendations need to be individualised to the clinical situation of each person with type 
2 diabetes.   
 
We have completed the first systematic review and meta-analysis examining the effects of 
age at type 2 diabetes diagnosis on all-cause mortality, microvascular and macrovascular 
 
 
complications. This comprehensive analysis, comprising over half a million participants, 
indicates that when adjusted for current age, younger age at type 2 diabetes diagnosis is 
associated with increased risk of mortality, macrovascular and macrovascular complications. 
Identification and quantification of the increased risk of mortality and vascular disease 
conferred by younger age at type 2 diabetes diagnosis may enable risk stratification of 
people in early in the condition and thereby provide greater opportunities for interventions to 
reduce risk of complication-associated morbidity and mortality for this increasing population 
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Amutha A., et al [41] 2017 2001-
ongoing 





Amutha A, Dutta et al [43] 2011 1992-2009 India 2630 28.2 NR Cohort Retinopathy 
Neuropathy 
Nephropathy 
Cai, X., et al [14] 2014 2004 -2011  China 3 100 57.1 60.7 Cohort Retinopathy 
Chan, J.C., et al [38]  2014 1995 – 
2009 
China 9 506 57.4 53.8 Cohort Macrovascular Disease 
Microvascular Disease 






Chen, M.S., et al [53]  1992 1985 – 
1986 
Taiwan 527 NR 55.0 Cross 
sectional 
Retinopathy 
Hamman, R.F., et al [54] 1989 1984 – 
1986 
USA 251 NR NR Cross 
sectional 
Retinopathy 
Huo, L., et al [52] 2018 1997-2011 Australia 743 709 60.2 46.0 Cohort All-Cause Mortality 





Kenealy, T., et al [25] 2008 2000–2005 New Zealand 67 563 60.5 
 
51.0 Cohort Macrovascular Disease 














Pavkov, M.E., et al [21] 2006 1965–2002 USA 3 653 40.9 61.9 Cohort All-Cause Mortality 
Nephropathy 
Pradeepa R, Rema M., et al [45] 2008 2001-
ongoing 
India 1629 50.4 55.4 Cross 
sectional 
Neuropathy 
Pradeepa R, Chella S., et al [44] 2014 2001-
ongoing 




Pradeepa R, Anjana RM., et al [42] 2010 2001-
ongoing 
India 1608 NR NR Cross 
sectional 
Microvascular Disease 
Penno et al [36]  2018 2006-2008 Italy 15 773 66.6 43.1 Longitudinal All-cause mortality 
 
Pugliese, G., et al [40] 2012 2007 – 
2008 
Italy 15 933 66.2 43.7 Cross 
sectional 
Macrovascular Disease 
Coronary Heart Disease 
Cerebrovascular Disease 
Retinopathy 
Rema, M., et al [46] 2005 2001-
ongoing 
India 1715 52.0 55% Cross 
sectional 
Retinopathy 
Romero-Aroca, P., et al [47] 2017 2007-2017 Spain 15 030 65.6 43.8 Longitudinal Retinopathy 
Nephropathy 
Song, S.H. and C.A. Hardisty [23] 2009 2008 UK 2 733 64.2 NR Cross 
sectional 
Macrovascular Disease 





Song, S.H. and T.A. Gray [48] 2011 NR UK 2 516 63.1 NR Cross 
sectional 
Retinopathy 
Thomas, R.L et al [49] 2015 2005 – 
2009 
UK 152 156c 67.4 68.6 Cohort Retinopathy  
Unnikrishnan, R. Anjana., et al [50] 2017 2005 – 
2009 











Unnikrishnan, RI, Rema M., et al [51] 2007 2005 – 
2009 




Wong, J., et al [15]  2008 1989 – 
2007 
Australia 1 476 65.0e 44.6 Cohort Retinopathy  






42 453 57.5 47.0 Cross 
sectional 










Republic  Estonia 









11 140 65.8 42.5 Cohort All-Cause Mortality 
Macrovascular Disease 
Microvascular Disease 
Coronary Heart Disease 
Cerebrovascular Vascular 
Disease 
Retinopathy Nephropathy  
aNumbers may vary slightly per outcome analysed, refer to the relevant meta-analysis NR= Not reported e=age at last examination 
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Figure Legends  
 
Figure 1: Flow chart of systematic review  
 
Figure 2: Effect of age at diagnosis (per 1 year increase), adjusted for current age on the risk of all-
cause mortality, macrovascular and microvascular disease. The symbols are proportional to the 
study weight and horizontal lines represent 95% confidence intervals.  
 
Figure 3: Effect of age at diagnosis (per 1 year increase), adjusted for current age on the risk of 
secondary outcomes. The symbols are proportional to the study weight and horizontal lines 
represent 95% confidence intervals. *For Unnikrishnan, R, Anjana RM., et al, older onset refers to 
those diagnosed aged >50 years and younger onset refers to those diagnosed aged ≤25 years 
 
